High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke

Stroke

Volumn 44, Issue 3, 2013, Pages 699-707

  Lapergue, Bertrand ^a,b,c   Dang, Bao Quoc ^a,b,c   Desilles, Jean Philippe ^a,b,c   Ortiz Munoz, Guadalupe ^a,b,c   Delbosc, Sandrine ^a,b,c   Loyau, Stéphane ^a,b,c   Louedec, Liliane ^a,b,c   Couraud, Pierre Olivier ^d   Mazighi, Mikael ^a,b,c   Michel, Jean Baptiste ^a,b,c   Meilhac, Olivier ^a,b,c   Amarenco, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d INSTITUT COCHIN   (France)

Author keywords

Blood brain barrier; Hemorrhagic transformation; High density lipoproteins; Ischemic stroke; Tissue plasminogen activator

Indexed keywords

CADHERIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; OXYGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN HEMATOMA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; IN VITRO STUDY; MALE; MEMBRANE PERMEABILITY; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84876283066     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.667832     Document Type: Article

References (49)

1. Khatri P, Wechsler LR, Broderick JP. Intracranial hemorrhage associated with revascularization therapies. Stroke. 2007;38:431-440.
2. Fitzpatrick AE, Noone I, O'Shea DD. Thrombolysis 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:2840; author reply 2841.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
4. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
5. Hjort N, Wu O, Ashkanian M, Sølling C, Mouridsen K, Christensen S, et al. MRI detection of early blood-brain barrier disruption: parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis. Stroke. 2008;39:1025-1028.
6. Neumann-Haefelin C, Brinker G, Uhlenküken U, Pillekamp F, Hossmann KA, Hoehn M. Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain. Stroke. 2002;33:1392-1398.
7. Benchenane K, López-Atalaya JP, Fernández-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in strokeinduced injury. Trends Neurosci. 2004;27:155-160.
8. Lapergue B, Moreno JA, Dang BQ, Coutard M, Delbosc S, Raphaeli G, et al. Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke. Stroke. 2010;41:1536-1542.
9. Paternò R, Ruocco A, Postiglione A, Hubsch A, Andresen I, Lang MG. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis. 2004;17:204-211.
10. Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem. 2008;283:25074-25081.
11. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352-1364.
12. Wang CX, Yang T, Shuaib A. An improved version of embolic model of brain ischemic injury in the rat. J Neurosci Methods. 2001;109:147-151.
13. Ponsin G, Pulcini T, Sparrow JT, Gotto AM Jr, Pownall HJ. High density lipoprotein interconversions in rat and man as assessed with a novel nontransferable apolipopeptide. J Biol Chem. 1993;268:3114-3119.
14. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561-565.
15. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab. 2009;29:119-129.
16. Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol. 2008;213:196-201.
17. Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke. 2001;32:1336-1340.
18. Paxinos GWC. The rat brain in stereotaxic coordinates. 6th ed. New York, NY: Academic Press; 1998.
19. Kelly MA, Shuaib A, Todd KG. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol. 2006;200:38-49.
20. Ortiz-Muñoz G, Houard X, Martín-Ventura JL, Ishida BY, Loyau S, Rossignol P, et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J. 2009;23:3129-3139.
21. Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, Carothers J. Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke. Stroke. 2002;33:1362-1368.
22. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-1874.
23. Dehouck MP, Jolliet-Riant P, Brée F, Fruchart JC, Cecchelli R, Tillement JP. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem. 1992;58:1790-1797.
24. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke. 2002;33:2115-2122.
25. Harris ES, Nelson WJ. VE-cadherin: at the front, center, and sides of endothelial cell organization and function. Curr Opin Cell Biol. 2010;22:651-658.
26. Liu W, Hendren J, Qin XJ, Liu KJ. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke. 2009;40:2526-2531.
27. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-pa therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
28. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatr. 2008;79:1093-1099.
29. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al.; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40: 2244-2250.
30. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al.; Multi MERCI Investigators. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39:1205-1212.
31. Zhu H, Fan X, Yu Z, Liu J, Murata Y, Lu J, et al. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab. 2010;30:1137-1146.
32. Lapergue B, Deroide N, Pocard M, Michel JB, Meilhac O, Bonnin P. Transcranial duplex sonography for monitoring circle of Willis artery occlusion in a rat embolic stroke model. J Neurosci Methods. 2011;197:289-296.
33. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
34. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
35. Cockerill GW, McDonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiemermann C. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J. 2001;15:1941-1952.
36. Sairanen T, Carpén O, Karjalainen-Lindsberg ML, Paetau A, Turpeinen U, Kaste M, et al. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke. 2001;32:1750-1758.
37. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917-925.
38. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-756.
39. Shehadah A, Chen J, Cui Y, Zhang L, Roberts C, Lu M, et al. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats. J Neurol Sci. 2011;309:96-101.
40. Amarenco P, Goldstein LB, Messig M, O'Neill BJ, Callahan A 3rd, Sillesen H, et al.; SPARCL Investigators. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke. 2009;40:2486-2492.
41. Makihara N, Okada Y, Koga M, Shiokawa Y, Nakagawara J, Furui E, et al. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry. Cerebrovasc Dis. 2012;33:240-247.
42. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
43. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084-1091.
44. Landmesser U, von Eckardstein A, Kastelein J, Deanfield J, Lüscher TF. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J. 2012;33:1712-1715.
45. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low hdl cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-22677
46. Kontush A, Chapman MJ. Lipidomics as a tool for the study of lipoprotein metabolism. Curr Atheroscler Rep. 2010;12:194-201.
47. Nobécourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 2005;48:529-538.
48. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151-155.
49. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27:257-260.